Abstract P6-08-11: Association between genetic testing for hereditary breast cancer and contralateral prophylactic mastectomy among young women diagnosed with early-stage breast cancer

Author(s):  
Julia E McGuinness ◽  
Boya Guo ◽  
Meghna S Trivedi ◽  
Tarsha Jones ◽  
Wendy K Chung ◽  
...  
2015 ◽  
Vol 22 (12) ◽  
pp. 3809-3815 ◽  
Author(s):  
Shoshana M. Rosenberg ◽  
Karen Sepucha ◽  
Kathryn J. Ruddy ◽  
Rulla M. Tamimi ◽  
Shari Gelber ◽  
...  

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e12572-e12572
Author(s):  
Kalatu R Davies ◽  
Abenaa M. Brewster ◽  
Patricia A. Parker ◽  
Isabelle Bedrosian ◽  
Melissa Crosby ◽  
...  

2016 ◽  
Vol 34 (7_suppl) ◽  
pp. 177-177
Author(s):  
Reshma Jagsi ◽  
Sarah T. Hawley ◽  
Kent A. Griffith ◽  
Nancy K. Janz ◽  
Allison W. Kurian ◽  
...  

177 Background: Contralateral prophylactic mastectomy (CPM) use is increasing in women who are not at increased risk of contralateral cancer development and will experience no survival benefit from the more morbid procedure. Little is known about treatment decision-making or provider interactions. Methods: We surveyed a weighted random sample of newly diagnosed patients with early-stage breast cancer who were treated in 2013-14, identified through the population-based SEER registries of Los Angeles and Georgia about 3 months after surgical treatment, and merged with SEER data (N=2632, RR=70%), to determine receipt of diagnostic tests and factors related to the decision about surgery (including knowledge and perceived physician recommendation). Results: Nearly half of 2,436 respondents with unilateral non-metastatic cancer considered CPM (25% strongly). Only 37% of those who considered CPM knew that it does not improve survival for all women with breast cancer (24% believed it does, 39% didn’t know). Among women receiving CPM, 37% believed it generally improves survival. Ultimately, 1,464 (60%) received BCS and 972 (40%) mastectomy (of whom 438, or 18% overall, received CPM). On multivariable analysis, pts who received CPM were younger, more likely to be white, and more likely to have a family history, private rather than Medicaid insurance, and received MRI. Even among pts without a deleterious genetic mutation or family history in multiple relatives (2,303), 400 (17%) received CPM. CPM was uncommon among pts who reported that their surgeons recommended against it (2.0% [17/832]) but much higher among those who reported no surgeon recommendation regarding CPM (21.3% [229/1,077]), and among those who perceived their surgeons to have recommended it (55.4% [147/265]). Conclusions: Many patients consider CPM, but knowledge is low. Use of CPM is substantial among patients without clinical indications but is low when patients report their surgeon recommended against it. In the context of shared decision-making, surgeon recommendations against CPM might help reduce potential overtreatment.


JAMA Surgery ◽  
2017 ◽  
Vol 152 (3) ◽  
pp. 274 ◽  
Author(s):  
Reshma Jagsi ◽  
Sarah T. Hawley ◽  
Kent A. Griffith ◽  
Nancy K. Janz ◽  
Allison W. Kurian ◽  
...  

2021 ◽  
Author(s):  
Vicky Ro ◽  
Julia E. McGuinness ◽  
Boya Guo ◽  
Meghna S. Trivedi ◽  
Tarsha Jones ◽  
...  

PURPOSE Increasing usage of multigene panel testing has identified more patients with pathogenic or likely pathogenic (P or LP) variants in low-moderate penetrance genes or variants of uncertain significance (VUS). Our study evaluates the association between genetic test results and contralateral prophylactic mastectomy (CPM) among patients with breast cancer. METHODS We conducted a retrospective cohort study among women diagnosed with unilateral stage 0-III breast cancer between 2013 and 2020 who underwent genetic testing. We examined whether genetic test results were associated with CPM using multivariable logistic regression models. RESULTS Among 707 racially or ethnically diverse women, most had benign or likely benign (B or LB) variants, whereas 12.5% had P or LP and 17.9% had VUS. Racial or ethnic minorities were twice as likely to receive VUS. Patients with P or LP variants had higher CPM rates than VUS or B or LB (64.8% v 25.8% v 25.9%), and highest among women with P or LP variants in high-penetrance genes (74.6%). On multivariable analysis, P or LP compared with B or LB variants were significantly associated with CPM (odds ratio = 4.24; 95% CI, 2.48 to 7.26). CONCLUSION Women with P or LP variants on genetic testing were over four times more likely to undergo CPM than B or LB. Those with VUS had similar CPM rates as B or LB. Our findings suggest appropriate genetic counseling and communication of cancer risk to multiethnic breast cancer survivors.


Sign in / Sign up

Export Citation Format

Share Document